Brief: PhaseBio Pharmaceuticals Q1 Loss Per Share $0.52

PhaseBio Pharmaceuticals

12/05/2020 21:18

May 12 (Reuters) - PhaseBio Pharmaceuticals Inc  PHAS.O :
    * PHASEBIO REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND
RECENT
BUSINESS HIGHLIGHTS
    * Q1 LOSS PER SHARE $0.52
    * Q1 EARNINGS PER SHARE ESTIMATE $-0.37 -- REFINITIV IBES
DATA
    * INITIATED PB2452 PHASE 3 TRIAL FOR REVERSAL OF
ANTIPLATELET
EFFECTS OF TICAGRELOR
    * PHASEBIO PHARMACEUTICALS -  COVID-19 PANDEMIC IS
TEMPORARILY
IMPACTING PACE OF SITE INITIATION & PATIENT ENROLLMENT FOR
PB2452 TRIAL
    * PHASEBIO PHARMA - INVESTIGATORS CONTINUE TO VIEW PB2452 AS
POTENTIAL OPTION TO HELP TREAT TICAGRELOR PATIENTS WHO NEED
EMERGENCY SURGERY
    * CASH AND CASH EQUIVALENTS AT MARCH 31, 2020 WERE $59.4
MILLION

Source text for Eikon:  ID:nBw5MGPLWa 
Further company coverage:  PHAS.O 

 ((Reuters.Briefs@thomsonreuters.com;))